LA JOLLA, Calif., Aug 1, 2016 /PRNewswire/ -- DermTech, Inc., an emerging diagnostics company focusing on non-invasive gene expression tests for skin cancer and inflammatory diseases, announced today the publication of, "Analytical Characteristics of a Noninvasive Gene Expression Assay for Pigmented Skin Lesions" in the August edition of ASSAY and Drug Development Technologies. This paper focuses on the analytical characterization of the Pigmented Lesion Assay (PLA) including qPCR specificity and sensitivity as well as the analytical performance of this 2 gene PLA.
Zuxu Yao, PhD, the lead author on the paper says, "We have made a great progress in the last 2 years on developing a non-invasive molecular diagnostic test to help dermatologists with the often difficult diagnosis of pigmented skin lesions such as melanomas or atypical moles. Our assay is currently commercially available in 49 of 50 states in the US. This paper shows how we improved the traditionally complex gene expression analysis to a simple and robust yet non-invasive 2-gene assay of high diagnostic sensitivity and specificity and describes the analytical characteristics of this assay. It is the first of a series of publications on this now optimized and robust molecular assay, which I believe will not only improve our understanding of melanoma biology, but most importantly also help clinicians in daily practice to improve the care for their patients and their diagnose of this lethal disease. We are really excited about this progress and look forward to more new developments of this assay moving forward."
DermTech is a commercial stage molecular dermatology company developing non-invasive gene expression tests to aid the clinical diagnosis of skin cancer and inflammatory skin conditions. DermTech operates a CLIA licensed and CAP accredited laboratory in the company's La Jolla, CA headquarters. DermTech's technology allows the analysis of skin biopsy samples collected non-invasively using an adhesive patch. DermTech provides highly accurate, objective information to the physicians to improve care and reduce costs. Current dermatologic diagnosis is primarily based on subjective visual pattern recognition that is prone to error and results in a substantial number of unnecessary surgical procedures. For additional information visit: www.dermtech.com.
Sarah Dennison, MBA
VP of Marketing
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/dermtech-announces-analytical-publication-300306610.html
SOURCE DermTech, Inc.